Puma Biotechnology Stock Today

PBYI Stock  USD 3.00  0.10  3.45%   

Performance

5 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Less than 5

 
High
 
Low
Very Low
Puma Biotechnology is trading at 3.00 as of the 24th of November 2024. This is a 3.45 percent increase since the beginning of the trading day. The stock's open price was 2.9. Puma Biotechnology has under 5 % chance of experiencing financial distress over the next 2 years but had a somewhat modest performance during the last 90 days. Equity ratings for Puma Biotechnology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
24th of April 2012
Category
Healthcare
Classification
Health Care
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company was founded in 2010 and is headquartered in Los Angeles, California. The company has 49.09 M outstanding shares of which 3.19 M shares are at this time shorted by private and institutional investors with about 14.34 trading days to cover. More on Puma Biotechnology

Moving together with Puma Stock

  0.62KZR Kezar Life SciencesPairCorr

Moving against Puma Stock

  0.79MTEM Molecular TemplatesPairCorr
  0.76MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.74NKTX Nkarta IncPairCorr
  0.67AGL agilon healthPairCorr
  0.66VALN Valneva SE ADRPairCorr
  0.65TPST Tempest TherapeuticsPairCorr

Puma Stock Highlights

ESG Sustainability
Environmental
Governance
Social
ChairmanAlan Auerbach
Thematic IdeaCancer Fighters (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Dow Jones Biotechnology, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.880.734
Fairly Up
Very volatile
Total Current Liabilities56.7 M99.4 M
Way Down
Slightly volatile
Non Current Liabilities Total68.1 M77.7 M
Fairly Down
Slightly volatile
Total Assets165.1 M230.5 M
Way Down
Slightly volatile
Total Current Assets127 M156.2 M
Significantly Down
Slightly volatile
Debt Levels
Puma Biotechnology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Puma Biotechnology's financial leverage. It provides some insight into what part of Puma Biotechnology's total assets is financed by creditors.
Liquidity
Puma Biotechnology currently holds 111.49 M in liabilities with Debt to Equity (D/E) ratio of 5.19, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Puma Biotechnology has a current ratio of 2.0, which is within standard range for the sector. Note, when we think about Puma Biotechnology's use of debt, we should always consider it together with its cash and equity.

Other Cashflows From Financing Activities

(18.17 Million)
Puma Biotechnology (PBYI) is traded on NASDAQ Exchange in USA. It is located in 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 and employs 185 people. Puma Biotechnology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 147.26 M. Puma Biotechnology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.09 M outstanding shares of which 3.19 M shares are at this time shorted by private and institutional investors with about 14.34 trading days to cover. Puma Biotechnology currently holds about 77.96 M in cash with 27.01 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Check Puma Biotechnology Probability Of Bankruptcy
Ownership Allocation
Puma Biotechnology owns a total of 49.09 Million outstanding shares. Over half of Puma Biotechnology's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Puma Ownership Details

Puma Stock Institutional Holders

InstituionRecorded OnShares
Kennedy Capital Management Inc2024-09-30
593 K
State Street Corp2024-06-30
514 K
Globeflex Capital, L.p.2024-09-30
452.6 K
Connor Clark & Lunn Inv Mgmt Ltd2024-06-30
354.5 K
Northern Trust Corp2024-09-30
317.7 K
Bank Of New York Mellon Corp2024-06-30
309 K
Winton Capital Group Ltd2024-09-30
309 K
Sei Investments Co2024-06-30
289.5 K
Qube Research & Technologies2024-06-30
273.2 K
Vanguard Group Inc2024-09-30
3.6 M
Blackrock Inc2024-06-30
3.6 M
View Puma Biotechnology Diagnostics

Puma Biotechnology Historical Income Statement

As of now, Puma Biotechnology's EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Total Operating Expenses is estimated to increase to about 153.4 M, while Other Operating Expenses is projected to decrease to under 174.6 M. View More Fundamentals

Puma Stock Against Markets

Puma Biotechnology Corporate Management

Jeffrey LudwigChief OfficerProfile
Alvin PharmdChief OfficerProfile
FRAPS BScPharmacovigilance, AffairsProfile
Bo ChaoSenior DevelopmentProfile
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.417
Earnings Share
0.47
Revenue Per Share
5.045
Quarterly Revenue Growth
0.435
Return On Assets
0.0973
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.